Therapeutic inhibition of the PD-1/PD-L1 pathway with PD-1 monoclonal antibodies reinvigorates immune cells’ ability to target cervical cancer cells, thus impeding cancer progression and enhancing SHP2 expression [20, 21]. This evidence concerns the gene PDCD1 and cervical cancer.